Danaher (DHR) Competitors

Danaher (NYSE:DHR) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Do institutionals and insiders have more ownership in DHR or RGEN?

79.1% of Danaher shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 11.1% of Danaher shares are held by company insiders. Comparatively, 1.2% of Repligen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Does the media prefer DHR or RGEN?

In the previous week, Danaher had 21 more articles in the media than Repligen. MarketBeat recorded 35 mentions for Danaher and 14 mentions for Repligen. Danaher's average media sentiment score of 1.39 beat Repligen's score of 0.95 indicating that Danaher is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Danaher	30 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Do analysts recommend DHR or RGEN?

Danaher currently has a consensus price target of $248.48, suggesting a potential upside of 30.79%. Repligen has a consensus price target of $170.75, suggesting a potential upside of 46.88%. Given Repligen's higher possible upside, analysts plainly believe Repligen is more favorable than Danaher.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Danaher	0 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.85
Repligen	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.69

Which has more risk & volatility, DHR or RGEN?

Danaher has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Repligen has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.

Which has preferable valuation and earnings, DHR or RGEN?

Danaher has higher revenue and earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than Danaher, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Danaher	$23.82B	5.71	$3.90B	$5.15	36.89
Repligen	$634.44M	10.29	-$25.51M	-$0.45	-258.33

Is DHR or RGEN more profitable?

Danaher has a net margin of 15.81% compared to Repligen's net margin of -3.93%. Danaher's return on equity of 10.80% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Danaher	15.81%	10.80%	6.89%
Repligen	-3.93%	4.53%	3.17%

Summary

Danaher beats Repligen on 12 of the 16 factors compared between the two stocks.